TranCel Corp. of Santa Ana, Calif., has appointed Floyd Benjaminpresident and chief executive, and Dr. Riccardo Calafiore vicepresident of research and medical affairs. Benjamin was seniorvice president of scientific affairs and chief operating officer ofthe Lyphomed Division of Fujisawa USA Inc. Calafiore isassistant professor of medicine and director of the laboratoryfor the study and transplantation of pancreatic islets at theUniversity of Perugia, Italy. TranCel is a privately helddevelopment-stage company focused on type I diabetesmellitus.

Schering-Plough Corp. of Madison, N.J., has appointed JacquesM. Chiller, Ph.D., president and chief executive officer of itsDNAX Research Institute in Palo Alto, Calif. He succeeds theretiring J. Allan Waitz, Ph.D. Chiller also has been named seniorvice president of Schering-Plough Research Institute, thecompany's pharmaceutical research arm. He had been a vicepresident of the Lilly Research Laboratories for Eli Lilly and Co.DNAX is focused on new immunological approaches to therapy.

Glycomed Inc. of Alameda, Calif., has appointed Gregory J.Giotta, Ph.D., chief intellectual property counsel. Giotta wasdirector of patents and trademarks for therapeutics at CetusCorp. Glycomed (NASDAQ:GLYC) is developing carbohydrate-based pharmaceuticals.

Alpha 1 Biomedicals Inc. (NASDAQ:ALBM) of Washington hasappointed Judith A. Hautala, Ph.D., vice president of corporatedevelopment. She was vice president of technologydevelopment at Genex Corp.

A. Kirk Field, Ph.D., has been named vice president of researchat Hybridon Inc. Field had been executive director of virologyof the Bristol-Myers Squibb Pharmaceutical Research Institute.Hybridon of Worcester, Mass., is developing therapeutics thatact by modulating gene expression.

ImmuLogic Pharmaceutical Corp. of Cambridge, Mass., hasappointed Martha J. Carter senior director of regulatory affairs.Carter had been vice president of regulatory affairs at SeronoLaboratories Inc. ImmuLogic (NASDAQ:IMUL) is developingtreatments for allergies and autoimmune diseases.

Dr. John D. Baxter has resigned from the board of CaliforniaBiotechnology Inc. (NASDAQ:CBIO) to pursue other drugdiscovery and biotechnology business opportunities, thecompany said.

David E. Robinson, the new president and chief executiveofficer of Ligand Pharmaceuticals, has been elected to theboard of Idec Pharmaceuticals Corp. Idec (NASDAQ:IDPH) of LaJolla and Mountain View, Calif., develops immunologicallyactive monoclonal antibodies.

(c) 1997 American Health Consultants. All rights reserved.